Kornimate/medical-research-clean huggingface dataset:
intestinal ischemia as a stimulus for systemic inflammatory response after cardiac arrest

Conditions: Cardiac Arrest; Reperfusion Injury

Summary: out-of-hospital cardiac arrest (ca) is a leading public health problem causing nearly one third of a million deaths annually in the us, accounting for half of all cardiovascular deaths and surpassing deaths from stroke, heart failure, and breast and lung cancer combined. twenty to fifty percent of ca patients (pts) can be resuscitated initially but many die before hospital discharge or suffer permanent neurologic damage. therapeutic hypothermia (th) improves survival and neurological outcomes. despite aggressive, targeted post arrest management, including th, approximately 50% of pts die before leaving the hospital due to global ischemia-reperfusion injury (iri) known as the "post arrest syndrome", 1 which is a sepsis-like state characterized by elevated markers of cellular inflammation and injury. it is believed that th works by decreasing the body's basal metabolic rate (bmr) and attenuating the systemic inflammatory response (sir). however, specific triggers of the intense pro-inflammatory response are unclear. this "gap" in knowledge must be closed to identify targeted therapy to decrease iri and improve outcomes. blood flow to the gut is decreased markedly and intestinal tissue becomes ischemic during ca and cpr, particularly when vasoconstrictor drugs such as epinephrine, are given. iri of the intestine increases intestinal permeability leading to intestinal microbial translocation and endotoxin release that can stimulate and perpetuate systemic inflammation and cause subsequent multi-organ dysfunction. endotoxin also increases body temperature and energy expenditure and may attenuate th induced reductions in bmr and hence, decrease efficacy. the purpose of this novel pilot study is to detect systemic endotoxin release following ca in humans and determine association with cytokine activation, and bmr alterations during th.

hypothesis 1 intestinal ischemia during and following caridac arrest leads to increased gut permeability and endotoxin release that stimulates the systemic inflammatory response that is responsible for subsequent death and disability after resuscitation. hypothesis 2: different degrees of systemic endotoxin activity variably affect basic metabolic rate during therapeutic hypothermia serial samples of blood, stool and expired gas will be measured at predetermined timepoints after rosc from cardiac arrest.

Eligibility criteria:
inclusion criteria: adult, cardiac arrest with rosc receiving therapeutic hypothermia- exclusion criteria: * age \< 18 * cardiac arrest of traumatic etiology * known to be pregnant * prisoner

Keywords: endotoxin cytokine metabolism
plasma levels of gdf-9 and gdf-15 in patients with polycystic ovary syndrome.

Conditions: Polycystic Ovary Syndrome

Summary: the purpose of this study is to determine the plasma levels of gdf-9 and gdf-15, and their association with bone and cardiovascular parameters in patients with polycystic ovary syndrome.


Eligibility criteria:
inclusion criteria: * female patients at ages 25-35 diagnosed with polycystic ovarian syndrome and idiopathic hirsutism exclusion criteria: * acute infectious disease, a thyroid, pituitary, nutritional, inflammatory, hepatic, renal, or neoplastic disorder; history of cardiovascular disease or pulmonary embolism; a family history of coronary artery disease; smoking history; hypertension; diabetes mellitus; use of oral contraceptives, anti-androgens and drugs known to interfere with cytokine release, such as corticosteroids, immunosuppressors, or nonsteroidal antiinflammatory drugs. any medication known to affect hormonal or metabolic parameters.
comparison of treatment for hoarding disorder

Conditions: Hoarding Disorder

Summary: this study proposes to compare two forms of treatment for hoarding disorder (hd), a common and impairing neuropsychiatric syndrome that has a profound impact on the lives and functioning of individuals, families, and society. specifically, we will compare a novel community-based group treatment led by individuals from the community who are not mental health professionals to the current standard of care treatment for hoarding disorder, cognitive behavioral therapy, conducted by psychologists in a group setting. we hypothesized that both treatment types will be similarly effective in reducing hoarding severity.

the study design for this proposal is a stratified, randomized, single-blind, non- inferiority trial comparing the current standard of care for treatment of hoarding disorder (hd), group cognitive behavioral therapy (g-cbt), to an innovative and promising community-based treatment, group buried in treasures (g-bit). participants will be stratified by gender, psychiatric status (high vs. low burden of psychiatric symptoms) and insurance status (insured vs. under- or un-insured) so that equal numbers of individuals with each of these characteristics are randomized to each treatment arm. they will then be randomly assigned (randomized) to either g-cbt or g-bit. participants will know which treatment group they are assigned to, but those members of the research team who are conducting clinical or neuropsychological assessments or analyzing the data will not; they will be blinded to participant group assignment, and group leaders will be blinded to the psychiatric status, neurocognitive status, insurance status, etc, of participants. the study is a non-inferiority trial, that is, the hypothesis to be tested is that g-bit is as effective, or no less effective, than g-cbt. we chose a non-inferiority design because we have no reason to believe g-bit is better than g-cbt and our preliminary data, as well as outcomes previously reported for g- cbt and g-bit, suggest that these treatments may have similar efficacies.

Eligibility criteria:
inclusion criteria: * diagnosis of hoarding disorder exclusion criteria: * individuals with active psychosis, schizophrenia, intellectual disability, or known dementia will be excluded * individuals who have participated in either cognitive-behavioral therapy for hoarding (group or individual) or in group buried in treasures in the past year

Keywords: compulsive hoarding clutter hoarding disorder
the efficacy of selenium as an alternative or complementary topical treatment of oral lichen planus

Conditions: Lichen Planus, Oral

Summary: evaluate clinically and biochemically the efficacy of topically applied selenium as complementary or alternative to triamcinolone acetonide 0.1% and tacrolimus 0.1% in patients with oral lichen planus.

the signs and symptoms of the oral lichen planus lesion. 2-the associated oral symptoms. 3- glutathione biomarker level as an antioxidant enzyme in saliva by elisa analysis .

Eligibility criteria:
inclusion criteria: * clinical diagnosis of olp exclusion criteria: 1. lichenoid reaction from medication ' . 2. any systemic autoimmune disease 3. pregnancy 4. smokers

Keywords: seleinum antioxidant glutathione-s-transferases reactive oxygen species
efficacy and safety of sodium oligomannate in the prevention of psci

Conditions: Ischemic Stroke

Summary: post-stroke cognitive impairment (psci) is a common complication of stroke, and seriously affect the quality of survival and the survival time in patients with stroke, psci is still lack of effective prevention and treatment measures, the study found that gut microbiota are closely associated with stroke and cognitive diseases, sodium oligomannate can improve cognitive function of mild-to-moderate alzheimer's disease (ad) , the expert consensus 2021 on the management of post-stroke cognitive impairment states that the role of sodium oligomannate in psci needs to be investigated in large sample clinical trials. this study intends to explore the efficacy and safety of sodium oligomannate in the prevention of psci in patients with acute ischemic stroke and cognitive impairment, so as to provide a potential intervention for the prevention of psci.

this clinical study was a randomized (1:1), double-blind, single-center, parallel controlled clinical study. the study period was 6 months to evaluate the efficacy and safety of sodium oligomannate in the prevention of psci in patients with ischemic stroke. patients with acute ischemic stroke were recruited. after signing informed consent, patients who met the inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive treatment in the trial group (receiving sodium oligomannate) or the control group (receiving placebo capsule). a total of 116 patients were enrolled.and safety assessment and survival follow-up were performed at 4 weeks, 12 weeks and 24 weeks, and efficacy assessment was performed at 12 weeks and 24 weeks.

Eligibility criteria:
inclusion criteria: * 1.the first occurrence of ischemic stroke, which met the diagnostic criteria of the chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018, was confirmed by ct or mr; 2. the onset of illness was less than 7 days after admission, aged 18-80 years; 3. clear consciousness, able to cooperate with cognitive and other tests, nihss score ≤15; 4. before onset, the patient's cognitive level was normal, daily life and social activities were normal; 5. stay in the current place of residence for more than 3 years; 6. with cognitive assessment, moca \< 22 (years of education \< 12, +1) after correction, and signed the informed consent. exclusion criteria: * 1.unable to cooperate with neuropsychological examination due to various reasons (such as consciousness disorders, vision disorders, hearing disorders, etc.); 2. combined with other diseases (such as intracranial mass, demyelinating disease, intracranial infection, neurodegenerative disease, epilepsy, severe heart, liver, kidney, blood system or other system diseases, etc.); 3. used antibiotics 3 months before onset; 4. a history of alcohol abuse, drug use, or serious mental illness (including major depression (hamd \> 10)) before onset of illness, 5. no stool was collected within 7 days of onset.

Keywords: post-stroke cognitive impairment gut microbiota sodium oligomannate
noacs for stroke prevention in patients with atrial fibrillation and previous ich

Conditions: Atrial Fibrillation; Intracerebral Hemorrhage

Summary: to determine the feasibility of a controlled trial examining the efficacy and safety of non-vitamin k antagonist oral anticoagulants (noacs) compared with asa for stroke prevention in patients with a high-risk of atrial fibrillation and previous intracerebral hemorrhage.

the naspaf-ich study is an open-label, randomized, controlled, phase ii study that will assess the feasibility of a controlled trial examining the efficacy and safety of non-vitamin k antagonist oral anticoagulants (noacs) compared with acetylsalicylic acid (asa) for stroke prevention in patients with high-risk atrial fibrillation and previous intracerebral hemorrhage, as well as provide evidence of efficacy and safety for planning of a phase iii trial. recruitment will occur at 10 high-volume stroke research centres across canada over 2 years, at which 100 adult patients with high-risk atrial fibrillation (chads2 ≥2) and previous spontaneous or traumatic ich (intraparenchymal or intraventricular hemorrhage while on or off anticoagulation) will be randomly assigned to receive a noac (particular agent at the discretion of the local investigator) or asa 81 mg per day. patients will be followed for a mean of 1 year to a common end-study date. the feasibility of recruitment will also be tested. the investigators estimate that five patients per year per centre can be recruited.

Eligibility criteria:
inclusion criteria: * previous primary intracerebral hemorrhage * atrial fibrillation (chads2 ≥ 2) exclusion criteria: * non-stroke indication for antiplatelet or anticoagulant therapy * recent intracerebral hemorrhage within 14 days * platelet count less than 100,000/mm3 at enrollment or other bleeding diathesis * prior symptomatic lobar intracerebral hemorrhage other than the qualifying event * uncontrollable hypertension consistently above sbp/dbp of 160/100 mmhg * known hypersensitivity to either asa or noacs * inability to adhere to study procedures
comparison of two strategies of glucocorticoid withdrawal in rheumatoid arthritis patients

Conditions: RheumatoId Arthritis

Summary: the purpose of this study is to compare the proportion of patients who could withdraw from prednisone and hydrocortisone one year after a progressive decrease of gc (gc tapering) or a hydrocortisone replacement therapy in rheumatoid arthritis in remission or low disease activity.

french multicenter double-blind controlled parallel-group randomized clinical trial phase iv assessing whether a hydrocortisone replacement therapy could increase the success rate of gc withdrawal at one year, in patients with rheumatoid arthritis in low disease activity or remission, in comparison to progressive decrease of gc (gc tapering).

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years old. * fulfilling the 2010 american college of rheumatology (acr)/eular criteria for ra. * treated with a stable dose of synthetic disease modifying anti-rheumatic drugs (sdmard) or biological disease modifying anti-rheumatic drug (bdmard) for at least 3 months. * who have been treated with prednisone or prednisolone for at least 6 months. * with a stable dose of prednisone or prednisolone of 5mg/day for at least 3 months. * with a das28 ≤3.2 for at least 3 months. * patients with health insurance * patients who have signed a written informed consent form. exclusion criteria: * any chronic condition that would need long term corticoid use (e.g. chronic lung diseases). * evidence of a flare within the last 3 months. * evidence of an allergy or intolerance to hydrocortisone or prednisone. * chronic idiopathic, or autoimmune clinical adrenal insufficiency. * gc joint injections within the last 3 months or scheduled in the next 3 months. * any gc intake expected more than \>5mg/day within the next 12 months. * association with sultopride and with live vaccines * significant trauma or major surgery within the 3 months prior to the baseline visit. * scheduled surgery in the next 12 months. * fibromyalgia. * foreseeable poor compliance with the strategy. * patient with any condition that would prevent participation in the study and completion of the study procedures, including language limitation. * alcohol and/or drug misuse as determined by the investigator. * pregnancy or breastfeeding. * patient is not willing to sign the informed consent. * juridical protection * das28\>3.2 after one month of a stable dose of prednisone 5 mg/day.

Keywords: low disease activity remission
collection of human tissue samples from the neck region for characterization of its molecular and biochemical signatures

Conditions: Obesity

Summary: the purpose of the study is to gather tissue (from the neck region), specimens (blood and urine) and medical record data from many patients and store them in one place so that scientists have the information they need to conduct research and learn about new ways to predict, identify and treat illness, specifically those related to obesity and diabetes.

this protocol is designed to actively collect biospecimens (specifically, tissue from the neck region) and clinical data for donation to the tri-md, specifically, dr. sparks' laboratory. these specimens and data will be available to dr. sparks for future research activity in accordance with the florida hospital and translational research institute for metabolism and diabetes (tri) policies.

Eligibility criteria:
inclusion criteria: * adults aged 18 and older presenting for surgery in the neck area * able to provide informed consent exclusion criteria: * unable to provide informed consent

Keywords: brown adipose tissue neck surgery
adaptive support ventilation in the weaning of copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: adaptive support ventilation (asv) is a closed loop ventilation mode that can act both as pressure support (psv) and pressure controlled (pcv) ventilation. weaning with asv shows promising results mainly in post-cardiac surgery patients. the aim of this randomized controlled study was to test the hypothesis that weaning with asv could reduce the weaning duration in patients with chronic obstructive pulmonary disease (copd) when compared with psv.


Eligibility criteria:
inclusion criteria: * diagnosis of copd * on invasive mechanical ventilation for at least 24 hours because of hypoxemic and/or hypercapnic respiratory failure exclusion criteria: * mechanical ventilation less then 24 hours (self extubation or death), * having a tracheotomy and * copd coexisted with severe cardiac or neurologic diseases.

Keywords: weaning adaptive support ventilation copd
the use of bone-borne guides in orthognathic surgery cases

Conditions: Dentofacial Deformities

Summary: the present study was conducted to evaluate a new design of the intermediate stent that is used in orthognathic surgery cases requiring le fort i osteotomy. the new design relied on referencing the maxillary segment to the zygomatic buttress. the study was carried out as a randomized controlled clinical trial in which 16 patients were enrolled according to the inclusion and exclusion criteria. in control group (n=8) conventional interocclusal splint was used and in study group (n=8) the proposed intermediate stent was used.

background: dentofacial deformities have many negative consequences in the form and function of head and neck region. this includes breathing, swallowing, speech and temporomandibular disorders. it is estimated that in about 19% of orthodontic patients, orthognathic surgery is required along with the orthodontic procedure. the introduction of cad/cam technology in orthognathic surgery planning has facilitated the procedure and allowed for more predicted results. aim of this study: the aim of the present study is to propose a new design of the intermediate stent that relates the mobilized maxilla to a fixed anatomical landmark in the skull which would allow for more accurate positioning of the maxilla during orthognathic surgery. materials and methods: this study was conducted on sixteen patients who have been undergone le fort i osteotomy procedure. eight of them (group a) were treated via a conventional stent while the other eight patients (group b) via a cad/cam bone-borne stent. postoperative patient evaluation was performed by comparing the predicted maxillary position to the resultant position postoperatively. this was done via 3d reconstruction ct scans.

Eligibility criteria:
inclusion criteria: * patients with dentofacial deformity requiring le fort i osteotomy exclusion criteria: * patients with severe asymmetry

Keywords: le fort orthognathic surgery virtual surgical planning
aswan heart centre - egyptian healthy volunteers

Conditions: Genetic Predisposition to Disease

Summary: to define the genotype of a healthy egyptian cohort as a crucial step in determining the possible clinical implications of mutations detected in patients recruited in the registry.

a key objective of the existing cardiomyopathies project is to develop and validate assays to identify the genetic and molecular determinants of inherited cardiomyopathies in the egyptian population. current sequencing technology has made cost- and time-effective whole exome and whole genome sequencing feasible. in their attempt to make clinically-relevant conclusions, genetecists, clinicians and bioinformaticians are increasingly faced by thousands of polymorphisms and variants, the clinical significance of which requires careful and systematic analysis of a number of factors including location of the mutation within the genome, type of mutation, gene affected and the protein for which it codes, functional importance of the coded protein, segregation within the family as well as frequency of the detected variation in the same population. the latter step requires defining what constitutes the "genetic norm" (including normal variants) within the reference population. data for different populations is already available in a number of databases that are accessible to the scientific community to help maximize the public benefit from research. examples include the exome aggregation consortium (exac) - which aggregates exome sequencing data from 60,706 unrelated individuals - and the 1000 genomes project which aggregates whole genome sequencing data from 2500 individuals. however, to be able to confirm novel gene variants in the egyptian population, data has to be compared to genomes of healthy individuals in the same population.

Eligibility criteria:
* inclusion criteria: * any adult egyptian citizen subject that considers him/herself free of cardiovascular disease. * exclusion criteria: * individuals under 18 years of age * known cardiovascular disease * known collagen vascular disease * individuals with communication difficulties, or who do not wish to participate * pregnancy * contraindication to mri * family history of sudden death * family history of a familial cardiomyopathy * family history of premature coronary artery disease (males \<40 years, females \<50 years). * withdrawal criteria: * withdrawal of consent.
ketorolac premedication for anesthetic efficiency of ianb & postendodontic pain in teeth with irreversible pulpitis

Conditions: Irreversible Pulpitis

Summary: the aim of this study to assess effect of ketorolac premedication on the effectiveness of the inferior alveolar nerve block, pretreatment and postoperative pain in patients with symptomatic irreversible pulpitis.

* patients will be clinically and radiographically examined and their eligibility will be assessed and preoperative pain will be measured. eligible patients will be treated in one visit. * patients will be randomly assigned to one of 2 groups: experimental group (taking a 10 mg tablet of ketorolac) and the control group (taking a placebo tablet). each tablet will be taken one hour before starting treatment. the patient's pain will be assessed before local anesthetic adminstration. after 15 minutes of the initial inferior alveolar nerve block (ianb), the teeth will be examined using a cold pulp sensitivity test; in case of no or mild pain, the treatment will be initiated. * during root canal treatment, no to mild pain response will be considered success. in case of failure, supplemental anesthesia will be administrated. * postoperative pain will be assessed 6, 12, 24 and 48 hours after treatment. the number of patients who will require rescue analgesic medication within the 48 hours postoperatively will be counted.

Eligibility criteria:
inclusion criteria: 1. age between 18-45 years old. 2. males or females. 3. mandibular posterior teeth with symptomatic irreversible pulpitis. 4. patients with non-contributory systemic condition. exclusion criteria: 1. patients allergic to any analgesics or antibiotics or anesthetics 2. pregnant females 3. if analgesics have been administrated during the past 8 hours before endodontic treatment. 4. irrestorable teeth.

Keywords: ketorolac premedication anesthetic efficiency post-endodontic pain post-operative pain irreversible pulpitis oral premedication